AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference

ALISO VIEJO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that the Company will present at the UBS 2010 Global Life Sciences Conference on Wednesday, September 22nd at 3:30 p.m. Eastern time (12:30 p.m. Pacific time) at the Grand Hyatt New York.  The UBS Global Life Sciences Conference provides industry leaders in the life sciences sector with the opportunity to present to top institutional investors.  

A live audio webcast of the presentation will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary software. An archive of the presentation at the UBS Global Life Sciences Conference will be available on the Company's website for 30 days.

About AVANIR

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.  As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones.  For more information about AVANIR, please visit www.avanir.com.  

SOURCE AVANIR Pharmaceuticals, Inc.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.